CD274 and osteosarcoma: Targeted immunotherapy with NC-6300 in combination with anti-PD-L1 antibody was found to potentiate immune checkpoint inhibition in mouse models of osteosarcoma and fibrosarcoma, and NC-6300 was even more effective than the MTD of DOX at increasing tumor growth delay induced by anti-PD-L1 antibody [164].